ScholarLens Back to search
2009•ChemotherapyRequires access

Ceftriaxone plus Conventional or Single-Daily Dose Amikacin versus Ceftazidime/Amikacin as Empiric Therapy in Febrile Neutropenic Patients

Franco Leoni, Stefania Ciolli, Anna Pascarella, Rosa Fanci, Roberto Caporale, P. L. Rossi Ferrini

Open publisher page 23 citations

Abstract

Results of antibiotic treatment in 144 febrile episodes during drug-induced granulocytopenia are reported. 63 episodes were treated with ceftazidime plus amikacin and 81 with ceftriaxone (CFX) using single daily doses combined with amikacin either divided in three doses (CFX-1 group) or administered as single doses (CFX-2 group). The response rates were 51, 80, and 57% respectively. In this study CFX was more effective than ceftazidime and amikacin provided better results when administered using the standard 8-hour scheduling.

About this research paper

What this paper is about

Results of antibiotic treatment in 144 febrile episodes during drug-induced granulocytopenia are reported. 63 episodes were treated with ceftazidime plus amikacin and 81 with ceftriaxone (CFX) using single daily doses combined with amikacin either divided in three doses (CFX-1 group) or administered as single doses (CFX-2 group). The response rates were 51, 80, and 57% respectively. In this study CFX was more effective than ceftazidime and amikacin provided better results when administered using the standard 8-hour scheduling.

Why it matters

OpenAlex reports 23 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Results of antibiotic treatment in 144 febrile episodes during drug-induced granulocytopenia are reported. 63 episodes were treated with ceftazidime plus amikacin and 81 with ceftriaxone (CFX) using single daily doses combined with amikacin either divided in three doses (CFX-1 group) or administered as single doses (CFX-2 group). The response rates were 51, 80, and 57% respectively. In this study CFX was more effective than ceftazidime and amikacin provided better results when administered using the standard 8-hour scheduling.

Key concepts: Amikacin, Ceftazidime, Ceftriaxone, Medicine, Empiric therapy, Cefepime, Cefotaxime, Febrile neutropenia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Ceftriaxone plus Conventional or Single-Daily Dose Amikacin versus Ceftazidime/Amikacin as Empiric Therapy in Febrile Neutropenic Patients — Research Paper | ScholarLens